research 315 Butyrophilin-like 2 (BTNL2) controls auto-aggressive dermal γδT lymphocytes that attack human hair follicles.
BTNL2 helps protect hair follicles from immune attacks.
Search
for
Sort by
Research
960-990 / 1000+ resultsresearch First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
research Malignant Melanoma
The document's conclusion cannot be provided because the document is not readable or understandable.
research Plastic Needle Shield: A Two-in-One Solution
The document's conclusion cannot be provided because the document is not accessible or understandable.
research Preparation, solubility, and anti-inflammatory effects of a complex of diphenylcyclopropenone/β-cyclodextrin derivatives as the treatment of alopecia areata
The DPCP/HPβCD complex improves solubility and anti-inflammatory effects for alopecia areata treatment.
research Autoimmune Hair Loss Induced by Alloantigen in C57BL/6 Mice.
Injecting certain cells into mice caused hair loss, which was preventable with a specific inhibitor.
research MAD2B acts as a negative regulatory partner of TCF4 on proliferation in human dermal papilla cells
MAD2B slows down the growth of skin cells that are important for hair development by interacting with TCF4.
research BH20 A multicentre analysis of the adequacy of alopecia horizontal biopsy samples over 10 years
Standardized forms and digital tools can improve alopecia biopsy diagnosis.
research Lymphoma Specialists Lament the Discontinuation of Underprescribed Bexxar
Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.
research Structural characterization and dissolution profile of mycophenolic acid cocrystals
The MPA-ISO cocrystal improved solubility and dissolution rate, while the others did not.
research Vemurafenib-induced pityriasis amiantacea: a case report
Vemurafenib can cause scalp issues but can be managed without changing the dose.
research Drug Breakdown: FINASTERIDE
research Polyglandular autoimmune syndrome type 4 with GAD antibody and dystonia
Dystonia may be part of PAS-4 and linked to immune issues.
research A polygenic mouse model of psoriasiform skin disease in CD18-deficient mice.
CD18-deficient mice developed psoriasis-like skin disease, useful for studying inflammatory skin disorders.
research Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
Rituximab may cause skin issues, but baricitinib can help improve them.
research Photobiomodulation mitigates DHT-induced apoptosis in dermal papilla cells via mitochondrial rescue and Wnt/TGF-β/BMP signaling modulation
Photobiomodulation helps protect hair follicle cells from damage caused by DHT.
research 5PSQ-056 Experience with tofacinitib and baricitinib in rheumatoid arthritis
Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
research Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.
research 17beta Hydroxysteroid Dehydrogenase Type 3 Inhibitors
The document's conclusion cannot be provided because the document is not available or cannot be read.
research Time-dependent 53BP1 foci kinetics in X-irradiated human hair follicle dermal papilla cells
53BP1 focus analysis in hair cells can help estimate radiation doses.
research Buschke-Ollendorff syndrome
Buschke-Ollendorff syndrome is a rare genetic disorder causing skin and bone changes, with some cases also showing ADHD or developmental delays.
research Drug-Induced Alopecia
research Formulation of chloroaluminum phthalocyanine incorporated into PS-b-PAA diblock copolymer nanomicelles
The PS-b-PAA copolymer nanomicelles are effective for delivering a cancer treatment drug in photodynamic therapy.
research Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
Baricitinib significantly regrows hair in severe alopecia areata patients.
research Bifunctional sodium hyaluronate microneedle patches integrating 5α-reductase and ROS regulation for boosted hair regeneration
The microneedle patch boosts hair growth by reducing DHT and oxidative stress.
research Letters to the Editors
Hair loss patients may often have Body Dysmorphic Disorder, and proper psychological assessment and treatment can help.
research (7E)-7,8-Dehydroheliobuphthalmin from Platycladus orientalis L.: Isolation, Characterization, and Hair Growth Promotion
DHHB from Platycladus orientalis L. promotes hair growth and could be a natural alternative to current treatments.
research Natural course of epidermolysis bullosa simplex with mottled pigmentation in a Japanese family with the p.P25L mutation in KRT 5
The p.P25L mutation in the KRT5 gene causes a rare skin condition that worsens over time and may lead to hair loss starting in young adulthood.
research Alopecia in Epidermolysis Bullosa
The document suggests that certain protein deficiencies and scalp blistering in Epidermolysis Bullosa may cause hair loss.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.